



IFWImage

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GEBAUER *et al.*

Appl. No.: 10/560,966

Filed: May 31, 2006

For: **Pyrazolopyrimidines**

Confirmation No.: 2373

Art Unit: 1754

Examiner: SAEED, Kamal A.

Atty. Docket: 2400.0140000/VLC/BLS

**Information Disclosure Statement
under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1** to **FP9** and **NPL1** to **NPL6** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and a patent application publication cited on the attached Form PTO/SB/08A, documents **US1** to **US3**, are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents, **FP1**, **FP3**, **FP7**, and **FP9**, cited on Form s PTO/SB/08A:

Document **FP1**, DE 31 30 633 A1, is in the German language. An English language equivalent of document FP1 is listed as document **US1**.

Document **FP3**, DE 38 20 538 A1, is in the German language. An English language equivalent of document FP3 is cited as document **FP2** and submitted herewith.

Document **FP7**, FR 2 794 745 A1, is in the French language. An English language abstract of document FP7 is cited as document **NPL4** and submitted herewith.

Document **FP9**, WO 2004/00844 A1, is in the German language. An English language abstract of document FP9 can be found on the face page of the published patent application.

Applicants' would also like to bring to the attention of the Examiner that, for the following document, the volume could not be determined to the best of the Applicants' ability: **NPL1**, Chesterfield, J., *et al.*, "Pyrimidines. Part VIII. Halogens and Hydroxing pyrimidines," *J. Chem. Soc.* :3478-3481, Royal Society of Chemistry (1955).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bryan L. Skelton
Attorney for Applicants
Registration No. 50,893

Date: MARCH 13, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

650561v1



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cormwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimballa
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey

Eldora L. Ellison
Donald R. Banowitz
Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Edward W. Yee
Virgil Lee Beaton
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis

Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
Young Tang
Christopher J. Walsh

W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek
Carla Ji-Eun Kim
Doyle A. Siever
Alexandra K. Pechhold
C. Matthew Rozier
Robert A. Schwartzman
Bryan L. Skelton
Ulrike Winkler

Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Julie A. Heider

Mita Mukherjee
Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to Federal Agencies

March 13, 2007

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8769
INTERNET ADDRESS:
BSKELTON@SKGF.COM

Art Unit 1754

Attn: Mail Stop Amendment

Re: U.S. Patent Application
Application No. 10/560,966; § 371 Filing Date: May 31, 2006
For: **Pyrazolopyrimidines**
Inventors: GEBAUER *et al.*
Our Ref: 2400.0140000/VLC/BLS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (1 sheet);
3. Form PTO/SB/08A (1 sheet);
4. Copies of fifteen (15) cited references (FP1 - FP9 and NPL1 - NPL6);
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 13, 2007
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Bryan L. Skelton".

Bryan L. Skelton
Attorney for Applicants
Registration No. 50,893

BLS/egw
Enclosure(s)

652123v1



Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/560,966		
		Filing Date	May 31, 2006		
		First Named Inventor	GEBAUER, Olaf		
		Art Unit	1754		
		Examiner Name	SAEED, Kamal A.		
Sheet	1	of	1	Attorney Docket Number	2400.0140000/VLC/BLS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/BK/	NPL1	Chesterfield, J., <i>et al.</i> , "Pyrimidines. Part VIII. Halogeno- and Hydrazino-pyrimidines," <i>J. Chem. Soc.</i> :3478-3481, Royal Society of Chemistry (1955)	
	NPL2	Novinson, T., <i>et al.</i> , "Novel Heterocyclic Nitrofurfural Hydrazones. In Vivo Antitrypanosomal Activity," <i>J. Med. Chem.</i> 19:512-516, American Chemical Society (1976)	
	NPL3	Novinson, T., <i>et al.</i> , "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyraolo[1,5-a]pyrimidines," <i>J. Med. Chem.</i> 20:296-299, American Chemical Society (1977)	
	NPL4	Dialog 351, Accession No. 10503903, Derwent WPI English language abstract for FR 2 794 745 A1 (listed on accompanying PTO/SB/08A as FP7) (2000)	
	NPL5	STNEasy Database, CAS Registry No. 185982-80-3, accessed March 9, 2007	
	NPL6	STNEasy Database, CAS Registry No. 185984-60-5, accessed March 9, 2007	

650537v1

Examiner Signature	/Bruck Kifle/ (02/29/2008)	Date Considered	02/29/2008
-----------------------	----------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.